⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now about polycystic kidney disease (PKD).

PKD is the most common inherited kidney disease, and it is now treatable — not just “watch and wait.” The common adult form, autosomal dominant PKD (ADPKD), affects roughly 1 in 1,000 people worldwide. Cysts grow slowly over decades. We can now predict who will progress fast and slow the disease in those people — a major change from a generation ago.
It usually runs in families, and each child of an affected parent has a 50% chance of inheriting it. But about 1 in 10 people have no family history (a new or “de novo” change). A blood/saliva genetic test can confirm the exact gene, which helps predict how the disease may behave.
Two main genes drive most ADPKD: PKD1 (usually more severe, kidney failure around the 50s–60s) and PKD2 (usually milder, kidney failure later, often 70s). Rarer genes (GANAB, DNAJB11, ALG9, IFT140) tend to be milder. A separate, rare, severe childhood form — autosomal recessive PKD (ARPKD, from the PKHD1 gene) — affects babies and children and also involves the liver.
High blood pressure is the earliest and most important treatable feature. It often starts years before kidney function drops. Controlling it well — usually with an ACE inhibitor or ARB — is one of the most powerful things you can do to protect your kidneys and heart. Home blood-pressure monitoring matters.
An MRI that measures your total kidney volume tells your doctor how fast you are likely to progress. This is the Mayo Imaging Classification (classes 1A–1E). Combined with your genes and history (the PROPKD score), it identifies who benefits most from disease-slowing medicine.
There is now a medicine that slows the disease: tolvaptan. For adults with rapidly progressing ADPKD, tolvaptan (Jynarque in the US; Jinarc elsewhere) slows cyst growth and the loss of kidney function. It makes you urinate a lot and feel thirsty, and it requires regular blood tests to watch the liver. It is not for everyone — it is targeted to those at high risk.
Drink enough water, eat less salt, keep a healthy weight, don’t smoke, and avoid frequent NSAID painkillers. These habits support kidney health. Generous water intake lowers the hormone (vasopressin) that drives cysts — though, honestly, large trials have not proven that prescribed high water intake slows the disease, so don’t over-drink to the point of discomfort.
Cyst problems are manageable. Pain, bleeding into a cyst (blood in the urine), cyst infections, and kidney stones can all be treated. Tell your team about new or severe symptoms.
Know the emergencies. A sudden, severe “worst-ever” thunderclap headache could mean a brain-aneurysm bleed — call emergency services immediately. Fever with kidney-area (flank) pain can mean a cyst infection — seek care promptly.
If kidneys eventually fail, transplant outcomes for PKD are excellent — often decades of good function, frequently with a living donor. Planning ahead (including checking relatives who might also carry the gene) improves results. Most people with PKD, with modern care, protect their kidney function longer and live full, active lives.

▼ Collapse

Important. This guide is educational and does not replace your own medical team. PKD care is highly individual — the right plan depends on your gene, kidney size, kidney function, age, and other health conditions. Always confirm decisions with your nephrologist (kidney specialist). If you are pregnant or planning pregnancy, several PKD medicines (including tolvaptan and ACE inhibitors/ARBs) must be stopped — talk to your team early.

Understanding PKD: The Big Picture

Polycystic kidney disease (PKD) is a condition in which fluid-filled sacs called cysts grow in the kidneys. Over time, the cysts multiply and enlarge, the kidneys grow much bigger than normal, and the healthy kidney tissue is gradually crowded out. This slow process can, over decades, reduce how well the kidneys filter the blood. PKD is the most common inherited kidney disease and one of the leading inherited causes of kidney failure worldwide.

There are two main kinds, and telling them apart matters because they behave very differently:

Autosomal dominant PKD (ADPKD) — by far the most common. It usually shows up in adulthood, runs in families in a “dominant” pattern (each child has a 50% chance), and affects roughly 1 in 1,000 people. Most of this guide is about ADPKD.
Autosomal recessive PKD (ARPKD) — rare and usually diagnosed in babies or young children. It needs two changed gene copies (one from each parent), and it affects the liver (a problem called congenital hepatic fibrosis) as well as the kidneys. ARPKD is covered in its own section below.

The headline. PKD is no longer a disease where doctors can only treat complications. Today they can predict how fast it will move, slow it with tolvaptan in those at highest risk, and powerfully protect the kidneys with good blood-pressure control — while managing pain, infections, liver cysts, and aneurysm risk along the way.

PKD is also a whole-body condition, not only a kidney condition. Beyond the kidneys, people with ADPKD may have cysts in the liver, a higher chance of brain aneurysms (weak spots in blood vessels), certain heart-valve quirks, pouches in the colon (diverticulosis), and hernias. The good news: each of these is screened for or managed in well-understood ways, which this guide walks through.

Your two kidneys are fist-sized filters. Every day they clean your blood, remove waste and extra fluid as urine, balance salts and minerals, help control blood pressure, and signal your body to make red blood cells and keep bones healthy. In PKD, cysts gradually replace working filter units (nephrons). Healthy kidneys weigh about 150 grams each; in advanced PKD a single kidney can weigh several kilograms. Because the kidney has enormous spare capacity, function often stays normal for years even as the kidneys enlarge — which is exactly why measuring kidney size (volume) predicts the future better than a single function test early on.

This is a general pattern, not a fixed timeline — everyone is different:

Childhood/teens (ADPKD): usually no symptoms; a few children have early high blood pressure or a few cysts on a scan done for another reason.
20s–40s: high blood pressure often appears; kidneys are enlarging but function is usually still normal. This is the key window for diagnosis, risk assessment, and starting blood-pressure control and (for high-risk people) tolvaptan.
40s–60s: kidney function may begin to decline, especially with PKD1; cyst pain, bleeding, infections, or stones may occur.
50s–70s+: some people reach kidney failure and need dialysis or transplant; many — especially with PKD2 or milder genes — never do.

Do I have the dominant adult form (ADPKD) or the recessive childhood form (ARPKD)?
How was my diagnosis made — by ultrasound, CT, MRI, or genetic testing?
What is my current kidney function (eGFR), and what stage of chronic kidney disease (CKD) am I in?
Who will coordinate my care — a general nephrologist, or a specialized PKD/inherited-kidney-disease clinic?
What extrarenal issues (liver, brain, heart, colon) should we be watching for in my case?
What should make me call you right away versus go to the emergency room?

Caregiver note. Because PKD is lifelong and inherited, it touches the whole family. A great early step is simply learning the vocabulary — ADPKD vs ARPKD, eGFR, total kidney volume, tolvaptan — so you can be a second set of ears at appointments. Keep one shared place (a notebook or phone note) for blood-pressure readings, medication names and doses, lab dates, and questions for the next visit.

Genetics & Family Testing: What Runs in the Family

PKD is caused by a change (mutation) in a single gene. Knowing which gene you have does two big things: it helps predict how your disease may behave, and it guides decisions about testing and family planning for relatives.

The dominant adult form (ADPKD)

“Autosomal dominant” means one changed copy of the gene is enough to cause the disease, and that an affected parent passes it to each child with a 50/50 chance, regardless of sex. The main genes:

PKD1 — the most common (about 78% of families) and generally the most severe. Kidney failure, on average, arrives earlier (often mid-50s). A specific kind of PKD1 change called “truncating” tends to be the most aggressive.
PKD2 — about 15% of families, generally milder, with kidney failure often a decade or two later (often 70s) and sometimes never.
Rarer genes — GANAB, DNAJB11, ALG9, IFT140 and others. These usually cause milder, sometimes atypical disease (for example, more liver cysts than kidney cysts, or fewer kidney cysts overall).

No family history? You can still have ADPKD. Roughly 10–15% of people have a brand-new (de novo) gene change, or a parent who had very mild disease that was never diagnosed. A condition called mosaicism (the change is in only some of the body’s cells) can also make disease milder and harder to detect.

The recessive childhood form (ARPKD)

ARPKD is different and rare (about 1 in 20,000 births). “Recessive” means a child must inherit a changed copy from both parents, who are usually healthy “carriers.” When two carriers have a child, each pregnancy has a 25% chance of ARPKD. It is caused mainly by the PKHD1 gene and affects both the kidneys and the liver (congenital hepatic fibrosis, which can cause high pressure in the portal vein). ARPKD is covered in more depth in the Diagnosis & Progression and Support sections.

Genetic testing is a blood or saliva test that reads your PKD genes. You do not always need it — many people are confidently diagnosed by imaging and family history alone. It is most useful when:

The diagnosis is unclear or atypical (for example, few cysts, or unusual liver involvement).
You are a potential living kidney donor for an affected relative and need to be sure you don’t carry the gene.
You want the most precise prognosis (e.g., to decide about tolvaptan), since the exact gene and mutation type refine risk.
You are planning a family and considering reproductive options such as preimplantation genetic testing (see below).

Limits to know: testing doesn’t always find the change (especially with mosaicism), it can reveal “variants of uncertain significance,” and results can carry emotional and (in some places) insurance implications. This is why pairing testing with a genetic counselor is so valuable — they help you decide whether to test, interpret results, and think through family communication.

People with ADPKD have several paths, and there is no single “right” one — it’s a personal decision best made with a genetic counselor:

Natural conception with or without testing during pregnancy.
Preimplantation genetic testing (PGT) — embryos created by IVF are tested, and only those without the family’s gene change are used. This can prevent passing ADPKD to a child but involves IVF, cost, and is not available everywhere.
Prenatal testing during a pregnancy, donor eggs/sperm, or adoption.

If you have ADPKD and may become pregnant, also plan ahead about medications: ACE inhibitors/ARBs and tolvaptan are stopped before and during pregnancy.

This is one of the most common — and most personal — questions in PKD. General points many specialists make:

Adults at risk can be tested when they choose, often around when blood-pressure monitoring and lifestyle steps would begin to matter (late teens to 20s). Knowing one’s status enables early blood-pressure control, which is protective.
Testing healthy children who have no symptoms is generally not routinely recommended, because there is usually no treatment to start in childhood and it raises consent, privacy, and insurance questions. An important exception: checking and treating blood pressure in at-risk children is reasonable, since early hypertension can occur.
Practices and family preferences vary — discuss timing with a nephrologist and genetic counselor.

Do I have ADPKD or ARPKD, and which gene is involved (PKD1, PKD2, a rarer gene, or PKHD1)?
Would genetic testing change my prognosis or treatment decisions? Should I do it now?
Can you refer me to a genetic counselor?
What is the risk to my children, siblings, and parents, and how should they be evaluated?
If I’m planning a family, what are my reproductive options, including preimplantation genetic testing?
If a relative wants to donate a kidney to me, how do we make sure they don’t also carry the gene?

Caregiver note. Inheritance news can be heavy — partners worry about children, and siblings face their own testing choices. You don’t have to have all the answers. Offering to attend the genetic-counseling appointment, and respecting that each adult relative gets to decide for themselves whether and when to test, is often the most supportive thing you can do.

How PKD Is Diagnosed — and How Fast It May Progress

Making the diagnosis

Most ADPKD is diagnosed with imaging plus family history:

Ultrasound is the usual first test — safe, inexpensive, no radiation. Doctors use age-adjusted criteria (often called the Pei/Ravine criteria): the number of cysts needed for a diagnosis rises with age, because a few simple cysts are common in older people anyway.
MRI (or sometimes CT) is more sensitive and is the tool used to measure kidney size precisely (see below). MRI uses no radiation and usually needs no contrast dye for PKD.
Genetic testing confirms the diagnosis when imaging is unclear — especially in younger adults, in people without a known family history, or when planning living-donor transplant.

Why young at-risk adults can be tricky. In someone under ~30 — particularly with the milder PKD2 gene — a normal ultrasound does not fully rule PKD out, because cysts may not be visible yet. MRI or genetic testing gives a more definite answer when certainty matters (for example, before donating a kidney).

Predicting the future: the single most empowering part of modern PKD care

This is the big shift. Doctors can now estimate how fast your disease is likely to progress, which tells you whether disease-slowing treatment is worth it. Two tools do most of the work:

On MRI, the radiologist measures your total kidney volume and adjusts it for your height (“height-adjusted total kidney volume,” or htTKV). Plotted against your age, this places “typical” ADPKD into a class from 1A (slowest-growing, lowest risk) to 1E (fastest-growing, highest risk).

1A–1B: slower progression; many never reach kidney failure.
1C–1E: faster progression; these are the people most likely to benefit from tolvaptan.

The beauty of this approach is that a single good MRI, done once, can forecast the likely path of your kidney function for years — because in ADPKD, bigger and faster-growing kidneys reliably predict faster loss of function. (This system was developed and validated by researchers at the Mayo Clinic and the CRISP study.)

The PROPKD score adds personal and genetic clues. It gives points for: being male (1 point), developing high blood pressure before age 35 (2 points), having a first urological event — blood in urine, cyst pain, or cyst infection — before age 35 (2 points), and the gene/mutation type (non-truncating PKD1 2 points; truncating PKD1 4 points). The total (0–9) sorts you into:

Low risk (0–3): median age of kidney failure around 71.
Intermediate (4–6): around 57.
High risk (7–9): around 49.

No score is perfect, and the imaging class and PROPKD score sometimes disagree — which is why doctors use them together, along with your eGFR trend over time, to judge your individual risk.

Tracking kidney function over time

Alongside imaging, your team follows your eGFR (estimated glomerular filtration rate — a blood-test measure of filtering, from creatinine), your urine for protein/blood, and your blood pressure. A faster yearly drop in eGFR is itself a sign of rapid progression. Tracking the trend over years matters more than any one value.

ARPKD is often suspected before or shortly after birth, when an ultrasound shows large, bright kidneys, sometimes with low amniotic fluid. Severely affected newborns can have breathing difficulty; others are diagnosed later in childhood. Because ARPKD also affects the liver (congenital hepatic fibrosis), children are watched for portal hypertension (high pressure in the liver’s blood supply, which can enlarge the spleen and cause varices) as well as kidney issues and high blood pressure. Care is led by pediatric nephrologists, often with liver (hepatology) specialists. Genetic testing of the PKHD1 gene confirms it. Many children today do well into adulthood with modern supportive care, though some need kidney (and occasionally liver) transplant.

How exactly was my PKD diagnosed, and is the diagnosis certain?
Do I need an MRI to measure my total kidney volume? What is my Mayo Imaging Class (1A–1E)?
What is my PROPKD score, and what does it suggest about my risk?
How fast is my kidney function (eGFR) changing year to year?
Am I considered a “rapid progressor”? Why or why not?
How often should I have imaging and blood tests going forward?
(If relevant) For my child with ARPKD: how will we monitor the liver and blood pressure, and who else should be on the care team?

Caregiver note. The risk tools can feel abstract. A practical way to help: write down the actual numbers from each visit — eGFR, blood pressure, Mayo class, PROPKD score — in one running list. Seeing the trend over time turns anxiety into information and makes the next conversation with the doctor far more productive.

Blood Pressure & Protecting Your Kidneys: The Foundation

If there is one thing within your control that protects your kidneys, it is blood-pressure control. High blood pressure (hypertension) is the earliest, most common, and most treatable feature of ADPKD — it often appears in the 20s or 30s, years before kidney function declines. Untreated, it speeds kidney damage and raises heart and stroke risk. Treated well, it is one of the most powerful protections you have.

Why ACE inhibitors and ARBs are usually first choice. In ADPKD, an overactive hormone system (the renin–angiotensin–aldosterone system, or RAAS) drives much of the high blood pressure. Medicines that block this system — ACE inhibitors (names ending in “-pril,” like lisinopril) and ARBs (ending in “-sartan,” like telmisartan or losartan) — target the root cause and protect the kidney. They are the recommended first-line blood-pressure medicines for most people with ADPKD.

What the research showed (the HALT-PKD trials)

Two large US trials called HALT-PKD studied blood-pressure control in ADPKD. In younger people with still-good kidney function, aiming for a lower blood-pressure target (about 95–110 / 60–75 mmHg) slowed the growth of the kidneys compared with standard control — without causing harm in that group. In people with more advanced disease, adding a second RAAS drug (an ARB on top of an ACE inhibitor) did not add benefit over a single ACE inhibitor. The practical takeaways: control blood pressure well, use an ACE inhibitor or ARB, and in younger people with preserved function, a tighter target may help — individualized to you.

Targets are individualized, but in general:

Younger adults (under ~50) with good kidney function who tolerate it: a tighter target (often around 110/75 or lower) may better protect the kidneys, based on HALT-PKD and reinforced by the 2025 international KDIGO guideline for high-risk patients.
Older adults or those with more advanced kidney disease or other conditions: a standard target (commonly under 130/80) balances protection against side effects like dizziness.

Tighter is not automatically better for everyone — very low pressure can cause lightheadedness and falls. Your team sets the right number for you.

Home readings are more reliable than occasional clinic checks for guiding treatment. Tips:

Use a validated upper-arm cuff (not wrist), correctly sized for your arm.
Sit quietly for 5 minutes first; back supported, feet flat, arm at heart level; no caffeine, exercise, or smoking for 30 minutes beforehand.
Take two readings a minute apart, morning and evening, and record them with date/time.
Bring your log (or app export) to appointments. Tell your team if readings are consistently high or if you feel dizzy.

Eat less salt (sodium). Lower salt helps blood pressure and may modestly help the kidneys. Aim for a moderate-sodium diet (your team can give a target); cooking at home and limiting processed foods does most of the work.
Drink enough water. Staying well hydrated lowers vasopressin, the hormone that drives cyst growth. Aim to keep your urine pale. Honesty check: large trials of prescribed high water intake have not proven it slows the disease, so drink to comfortable, steady hydration — don’t force large volumes to the point of discomfort or overnight disruption, and ask your team if you have advanced kidney disease or heart issues.
Maintain a healthy weight and stay active — good for blood pressure, heart, and overall kidney health.
Don’t smoke. Smoking harms blood vessels and kidneys (and raises aneurysm risk).
Limit alcohol and be cautious with caffeine if your blood pressure is hard to control.
Avoid kidney-harming medicines. Frequent use of NSAID painkillers (ibuprofen, naproxen) can stress the kidneys — use sparingly and ask before regular use. Be cautious with certain herbal/“detox” products, which are unregulated and occasionally toxic to kidneys.

A note on supplements and “natural kidney cleanses.” No herbal product, supplement, or detox regimen has been proven to slow PKD, and some can harm the kidneys or interact with your medicines. Always tell your nephrologist and pharmacist about everything you take, including over-the-counter and herbal products. Supplements are not a substitute for proven care like blood-pressure control and (when indicated) tolvaptan.

What is my target blood pressure, given my age and kidney function?
Am I on an ACE inhibitor or ARB? If not, why not?
Should I monitor my blood pressure at home, and how often?
How much salt should I aim for, and how much water should I drink?
Which painkillers are safe for me, and which should I avoid?
Are there supplements or medicines I’m taking that I should stop?

Caregiver note. Blood-pressure control is a daily team effort. Practical help: set a phone reminder for medication times, keep the cuff in an easy spot, take readings together at the same times each day, and help cook lower-salt meals. If your loved one is starting an ACE inhibitor/ARB, watch for dizziness on standing in the first weeks and report a dry cough (a known ACE-inhibitor side effect that an ARB can replace).

Tolvaptan & Managing Cyst Complications

Tolvaptan: the first medicine that slows PKD

Tolvaptan (brand names Jynarque in the US; Jinarc in Europe, Japan, Canada, and elsewhere) is the first — and so far only — drug shown to slow ADPKD itself, rather than just treat complications. It blocks vasopressin at the kidney (a “vasopressin V2-receptor antagonist”), turning down the signal that drives cyst growth.

What it does, in plain terms. In adults with rapidly progressing ADPKD, tolvaptan slows how fast the kidneys enlarge and how fast kidney function declines. In the major trials, it reduced the yearly loss of kidney function by roughly 1 mL/min — which adds up over years and can delay dialysis or transplant. It does not cure PKD or shrink kidneys, and it works best started earlier, while there is still function to protect.

The evidence (TEMPO 3:4 and REPRISE)

Two large trials anchor tolvaptan’s approval. TEMPO 3:4 (3 years, earlier-stage disease) showed tolvaptan slowed both kidney growth and function loss. REPRISE (1 year, later-stage disease) confirmed the benefit on kidney function in people with more advanced CKD. Together they led to approval in Japan (first, 2014), Europe and Canada, and the United States (2018).

Who is a candidate?

Tolvaptan is targeted — it is for adults with ADPKD who are at risk of rapid progression (for example, a higher Mayo Imaging Class, a concerning PROPKD score, or a documented fast eGFR decline), and who can commit to the monitoring. It is not recommended for everyone with PKD; for slow progressors, the side-effect burden may outweigh the benefit.

Because tolvaptan makes the kidneys release a lot of free water, the most noticeable effects are frequent urination, large urine volumes, intense thirst, and waking at night to urinate. This is called aquaresis. It is not dangerous if you keep up with fluids, but it is a real lifestyle commitment.

You’ll drink substantial water through the day and keep some at the bedside.
The dose is usually split (a larger morning dose, a smaller afternoon dose); some people time the second dose to limit nighttime bathroom trips, guided by their team.
Doses are increased gradually (titrated) to the highest you tolerate.
Other possible effects: thirst, dry mouth, fatigue, and (because you’re flushing fluid) the need to plan around bathroom access — many people adapt with time.

Uncommonly, tolvaptan can injure the liver. To catch this early and keep it reversible, liver blood tests are mandatory: before starting, then monthly for the first 18 months, then every 3 months thereafter. In the US this is organized through a formal safety program (called a REMS); other countries have equivalent monitoring. Do not skip these tests. Tell your team right away about symptoms like unusual tiredness, loss of appetite, nausea, right-upper-belly pain, dark urine, pale stools, itching, or yellowing of the skin/eyes. If liver tests rise, the drug is paused; the injury almost always reverses when caught early.

Tolvaptan and pregnancy. Tolvaptan must not be used in pregnancy and is stopped before trying to conceive. If you can become pregnant, discuss reliable contraception and planning with your team before starting.

Managing cyst complications

Most cyst problems are very treatable. Knowing what to watch for — and which are emergencies — helps you act fast.

Chronic dull flank/back pain from heavy, enlarged kidneys is common. Approaches: heat, physical therapy and posture, paracetamol/acetaminophen (preferred over NSAIDs, which can stress kidneys), and for some people nerve-targeted treatments or, rarely, procedures to drain or shrink large painful cysts. Sudden, severe pain can mean bleeding, infection, or a stone — see below. A dedicated PKD pain plan with your team is worthwhile if pain is affecting daily life.

A cyst can bleed, causing sudden flank pain and visible blood in the urine. Most episodes settle on their own with rest, extra fluids, and pain control over a few days. Seek care if bleeding is heavy, you pass clots, you have fever, you feel faint, or it doesn’t improve — occasionally imaging or a procedure is needed.

A cyst can become infected, typically causing fever plus localized kidney-area (flank) pain, sometimes with feeling unwell. This needs prompt medical care. Importantly, ordinary antibiotics don’t always penetrate cysts well; doctors choose ones that get inside cysts — commonly fluoroquinolones (like ciprofloxacin) or trimethoprim-sulfamethoxazole — often for a longer course. Cyst infection can be hard to tell apart from cyst bleeding (both cause pain); fever and lab/imaging clues help. Don’t try to self-treat a suspected cyst infection — call your team.

Stones are more common in PKD. Signs include severe waves of flank pain, blood in urine, and nausea. Management is similar to stones in anyone — fluids, pain control, and sometimes procedures — but the altered anatomy of PKD kidneys can make some treatments trickier, so care at a center familiar with PKD helps. Staying well hydrated and following any dietary advice helps prevent recurrence.

Red flags — seek urgent care. Fever with flank pain (possible cyst infection); heavy bleeding, clots, or feeling faint; severe uncontrolled pain; and above all a sudden, severe “thunderclap” headache unlike any before (possible brain-aneurysm bleed — call emergency services immediately; see the next section).

Am I a candidate for tolvaptan? What are the expected benefits for me?
What side effects should I expect, and how do we handle the urination and thirst?
Exactly when are my liver blood tests due, and how will I be reminded?
What symptoms mean I should call you or stop the medicine?
How do we manage my cyst pain without harming my kidneys?
If I get fever with flank pain, what should I do, and which antibiotics work for cyst infections?
What’s my plan if a cyst bleeds or I see blood in my urine?

Caregiver note. Tolvaptan is one of the more demanding routines in medicine — the constant urination and thirst can be exhausting and socially awkward (planning around bathrooms, broken sleep). You can help enormously by normalizing it, keeping water bottles filled, protecting nighttime rest where possible, and — crucially — guarding the liver-test schedule (put every monthly lab date on a shared calendar with reminders). Also learn the two key emergencies: fever + flank pain (cyst infection) and sudden thunderclap headache (possible aneurysm).

Beyond the Kidneys: Liver Cysts & Brain-Aneurysm Screening

ADPKD affects more than the kidneys. Two extrarenal issues matter most to know about: liver cysts (very common, usually harmless) and brain aneurysms (uncommon, but important because of screening).

Polycystic liver disease

Most adults with ADPKD develop cysts in the liver as they age. The great majority cause no problems at all and don’t affect liver function. Liver cysts are more common and tend to grow larger in women, partly because of estrogen — which is why hormone therapy (estrogen, and possibly progesterone) may be discouraged or used cautiously if liver cysts are significant.

In a minority, the liver becomes very enlarged, causing fullness, early satiety (feeling full quickly), shortness of breath, or pain. Options, chosen carefully and usually at specialized centers, include:

Medicines: somatostatin analogs (octreotide, lanreotide) can modestly reduce liver (and kidney) volume in selected people.
Procedures: draining/sclerosing a single dominant cyst, “fenestration” (surgically unroofing cysts), or, for severe cases, partial liver resection.
Avoiding estrogen-containing hormones if liver disease is significant.
Liver transplant — rarely, for the most severe, disabling polycystic liver disease (sometimes combined with kidney transplant).

Liver cysts can occasionally become infected or bleed (similar warning signs to kidney cysts: fever, new pain) — report these.

Brain (intracranial) aneurysm screening

People with ADPKD have a somewhat higher chance of an intracranial aneurysm — a weak, balloon-like spot on a brain artery. Most aneurysms never cause trouble, but if one ruptures it causes a dangerous bleed (subarachnoid hemorrhage). The reassuring part: in the right people, we can screen for aneurysms with a brain scan and treat ones that need it.

Who is usually screened. Screening (with an MRA — a special MRI of brain arteries, no contrast or radiation needed) is generally offered to people with ADPKD who have a family history of brain aneurysm or brain bleed, those in high-risk jobs (where a sudden event would endanger others, e.g., pilots), those needing major surgery, or those who are simply very anxious and want to know. Not everyone needs routine screening — practice varies by region and family history. Your team will advise based on your situation.

Many aneurysms are tiny and low-risk and are simply monitored with periodic scans, plus strict blood-pressure control and not smoking. Larger or higher-risk aneurysms can be treated by neurosurgery or by a minimally invasive procedure threaded through the blood vessels (endovascular coiling). A specialist (neurosurgeon/neuroradiologist) weighs the small risks of treatment against the risk of rupture. If your first screen is clear and you’re higher-risk, your team may repeat it every several years.

Emergency — know this sign. A sudden, severe, “worst headache of my life” (thunderclap headache), especially with neck stiffness, vision changes, vomiting, confusion, or loss of consciousness, is a medical emergency — call emergency services immediately. This could be an aneurysm rupture, and fast treatment saves lives.

Heart valves: mild valve quirks (like mitral valve prolapse) are more common but usually need no treatment; tell your doctor of palpitations or breathlessness.
Diverticulosis: small pouches in the colon are more common; a high-fiber diet helps, and report significant abdominal pain or bleeding.
Hernias: abdominal-wall and inguinal hernias occur more often, partly from large kidneys/liver; they are repaired as in anyone when needed.

Do I have liver cysts, and are they likely to cause problems?
If I’m a woman, how do liver cysts affect decisions about hormone therapy or contraception?
Should I be screened for a brain aneurysm, given my family history and job?
If I’m screened and it’s clear, when (if ever) should I be re-screened?
What exactly should I do if I get a sudden severe headache?

Caregiver note. The single most important caregiver fact in this section is the thunderclap headache rule: a sudden “worst-ever” headache is a 911 emergency, not something to “wait and see.” Make sure everyone in the household knows it. For liver issues, watch for new fullness, weight changes, or breathlessness and mention them at visits.

Planning for Kidney Failure (If It Comes)

Many people with PKD — especially with milder genes or low-risk imaging classes — never reach kidney failure. For those who do, it usually arrives gradually over years, giving time to plan. Planning ahead is one of the strongest predictors of doing well. “Kidney failure” (also called end-stage kidney disease) means the kidneys can no longer filter enough on their own, and you’ll need kidney replacement therapy: a transplant or dialysis.

The best-case path: a transplant before you ever need dialysis. A “preemptive” transplant — ideally from a living donor — done before dialysis is needed, generally gives the best outcomes. That’s why your team starts transplant conversations and donor evaluation early, often when eGFR is still in the low 20s, well before you feel sick.

Understanding your options

People with PKD generally do very well with kidney transplant — often better than average, because PKD doesn’t come back in the new kidney and many patients are otherwise healthy. A transplant can come from a living donor (a relative or friend) or a deceased donor. Living-donor transplants tend to last longer and can be scheduled, including preemptively. The next section (“Transplant & Living Well”) covers this in detail, including the special step of screening related donors for the PKD gene.

If transplant isn’t immediately available, dialysis does the filtering. Two main types:

Hemodialysis — blood is cleaned by a machine, usually 3 times a week at a center (or at home for some). It needs vascular access (a fistula in the arm), created months ahead, so plan access early.
Peritoneal dialysis — done at home using the lining of your abdomen, often overnight. PKD consideration: very large kidneys/liver can crowd the abdomen and sometimes make peritoneal dialysis harder, though many people with PKD use it successfully.

Dialysis is a bridge to transplant for many, and a good long-term option for others. Your team helps match the choice to your anatomy and life.

Usually not — most people keep their native kidneys, even at transplant. Removing a native kidney (nephrectomy) is considered only for specific reasons: recurrent serious cyst infections or bleeding, severe pain, stones, suspicion of cancer, or simply not enough room in the abdomen to place the new kidney. When needed, it may be done before, during, or after transplant; timing is individualized. It’s a bigger operation, so it’s reserved for clear indications.

As eGFR falls, your team manages the downstream effects to keep you feeling well: anemia, bone/mineral balance, acid levels, potassium, fluid, and blood pressure. A kidney dietitian tailors diet to your stage (this changes over time — what’s right at CKD stage 3 differs from stage 5). Staying active, managing other conditions (diabetes, heart disease), and keeping vaccinations up to date all matter. Many people work and travel throughout this phase.

How close am I to needing kidney replacement therapy, and what’s my eGFR trend?
When should we start transplant evaluation, and can I aim for a preemptive (pre-dialysis) transplant?
Should I look for a living donor now? How do we screen relatives for the gene?
If I need dialysis, which type fits my anatomy and life — and when should access be created?
Will my native kidneys need to be removed? If so, when?
Can I meet a kidney dietitian and a social worker to plan ahead?

Caregiver note. This stage involves big decisions and lots of appointments — transplant work-ups, dialysis education, possibly donor evaluation. Helping with logistics (scheduling, transport, insurance paperwork, note-taking) reduces the load enormously. If you’re considering being a living donor yourself, know that for related donors there’s an extra step — making sure you don’t carry the PKD gene (see the next section).

Transplant & Living Well

For most people with PKD who reach kidney failure, transplant is the goal — and the outcomes are genuinely excellent, frequently giving decades of good kidney function and freedom from dialysis. Because PKD doesn’t recur in the transplanted kidney, and because many PKD patients are otherwise healthy, they often do better than the average transplant recipient.

Living-donor transplant: often the best, and frequently possible. A kidney from a living donor (related or unrelated) usually lasts longer than a deceased-donor kidney and can be scheduled — even before you need dialysis. Family members often want to help, which is wonderful, but in PKD there’s a crucial extra check.

If a blood relative wants to donate, the transplant team must confirm that the donor does not also have ADPKD — otherwise they could develop kidney disease themselves later, and the donated kidney might carry the condition. This is done with careful imaging adjusted for the donor’s age (often MRI) and, when needed, genetic testing — especially for younger relatives, where imaging alone can’t fully rule it out. Unrelated donors (a spouse or friend) don’t carry this concern. A good transplant center handles this routinely; it’s a reason to choose a program experienced in PKD.

Evaluation: tests to confirm you’re a candidate (heart, infections, cancer screening, mental health, social support). Native-kidney size and any need for nephrectomy are assessed here.
Finding a donor / listing: identify a living donor, and/or join the deceased-donor waiting list.
The transplant: the new kidney is usually placed low in the abdomen; your own kidneys typically stay in place.
After: lifelong anti-rejection (immunosuppressant) medicines, frequent early monitoring, then settling into routine follow-up. Most people return to active life, work, and travel.

PKD is lifelong, and living well is about more than labs:

Stay engaged with care: keep blood pressure controlled, take medicines reliably, attend follow-ups, and keep vaccines current (especially important on immunosuppression after transplant).
Mental health matters: a chronic, inherited condition can bring anxiety, “survivor” feelings, or worry about children. Counseling and peer support help — you are not alone.
Connect with others: the PKD Foundation’s chapters, peer mentors, and community can be a lifeline for practical tips and encouragement.
Plan life around the disease, not the reverse: with modern care, most people with PKD work, raise families, exercise, and travel for many years.

Many women with ADPKD have healthy pregnancies, but it deserves planning. Risks are higher for high blood pressure and preeclampsia, particularly if blood pressure or kidney function is already affected. Key steps: plan with your nephrologist and an obstetrician experienced in kidney disease before conceiving; stop ACE inhibitors/ARBs and tolvaptan before pregnancy (they can harm the baby); monitor blood pressure closely throughout and after; and watch for preeclampsia signs (rising blood pressure, swelling, headaches, vision changes). With good care, outcomes are generally good.

Am I a transplant candidate, and can I aim for a living-donor and/or preemptive transplant?
If a relative wants to donate, how will you make sure they don’t carry the PKD gene?
Will I need my native kidneys removed before or at transplant?
What are realistic outcomes and life expectancy for someone like me after transplant?
What support exists for the emotional side — counseling, peer mentors, support groups?
(If relevant) I’m planning pregnancy — which medicines do I stop, and who should be on my care team?

Caregiver note. Transplant is a marathon with the recipient and, often, a donor in the family. Support both. Practical help: attend the evaluation visits, help track the many pre-transplant tests, prepare the home for recovery, set up a reliable system for the strict post-transplant medication schedule, and watch for early warning signs of infection or rejection (fever, reduced urine, swelling, pain over the transplant) that the team will teach you.

Support & Resources

This section pulls together the practical extras: a dedicated caregiver toolkit, how to find and join clinical trials, an honest list of treatments that have not worked, where to get expert care (Utah and beyond), how access differs around the world, a plain-language glossary, and the key references behind this guide.

Caregiver Toolkit (Notes & Practical Tips)

For caregivers — the essentials in one place. Supporting someone with PKD is a long-haul role. You don’t need to be a medical expert; you need a few reliable systems and to know the emergencies.

Blood pressure: help take and log home readings at consistent times; keep a validated arm cuff handy; flag consistently high readings or dizziness.
Medications: set reminders; keep an up-to-date list (names, doses, times) on a shared phone note; reorder refills before they run out.
If on tolvaptan: keep water available everywhere; protect sleep where you can; and above all guard the liver-test schedule — monthly for 18 months, then every 3 months. Put each date on a shared calendar with alerts.
Diet: support lower-salt cooking and steady hydration; involve the kidney dietitian for stage-specific advice.
Appointments: attend when you can, take notes, and keep the running list of numbers (eGFR, blood pressure, Mayo class, PROPKD score) and questions.

Sudden “worst-ever” thunderclap headache (± neck stiffness, vomiting, vision change, confusion) → call emergency services now (possible brain-aneurysm bleed).
Fever with kidney-area (flank) pain → seek care promptly (possible cyst infection needing special antibiotics).
Sudden flank pain with blood in urine → rest, fluids, pain control; seek care if heavy bleeding, clots, fever, or feeling faint (possible cyst hemorrhage).
On tolvaptan — signs of liver trouble (unusual fatigue, nausea, loss of appetite, right-upper-belly pain, dark urine, yellow skin/eyes) → contact the team right away.

Because PKD is inherited, families carry extra weight — worry about children, guilt, and the strain of a lifelong condition. Helpful approaches: let each adult relative make their own testing decisions; offer to attend genetic counseling together; watch for signs of depression or burnout (in the patient and yourself); and connect with peer support. Caregiver burnout is real — protect your own health and lean on respite and community resources.

>Clinical Trials — Finding and Joining

Research is global and active. Joining a trial can give access to new approaches and helps everyone with PKD. Trials are voluntary, carefully monitored, and you can leave at any time.

How to search. Use ClinicalTrials.gov (search “ADPKD” or “polycystic kidney disease”) and the PKD Foundation’s clinical-studies finder (clinicalstudies.pkdcure.org). Ask your nephrologist or a PKD center of excellence about trials that fit you. Outside the US, check the EU trials portal (CTIS), the UK and national registries, Japan’s jRCT, China’s ChiCTR, and the WHO portal (trialsearch.who.int).

These illustrate the kinds of research underway. Always confirm current recruiting status on ClinicalTrials.gov — trials open and close over time.

Farabursen (RGLS8429) — an experimental injection that blocks a molecule (miR-17) driving cyst growth. A Phase 1b study completed in 2025 with encouraging early signals; later-stage trials are anticipated. Search ClinicalTrials.gov for the latest.
Metformin — an inexpensive, repurposed diabetes pill. The Phase 2 TAME-PKD trial (NCT02656017) showed it is safe and tolerable in ADPKD, but did not prove it slows the disease; larger trials are needed.
Tolvaptan in children/adolescents — studied to see whether starting earlier helps; ask pediatric nephrology if relevant.
Hydrochlorothiazide (HYDRO-PROTECT, NCT05373264) — testing a common diuretic to ease tolvaptan’s excessive urination and possibly help kidneys.
Prescribed high water intake — studied in the Australian PREVENT-ADPKD trial (registry ANZCTR12614001216606) and the UK DRINK feasibility study; results have not shown a clear slowing of the disease, which is why water is encouraged for general health rather than as a proven treatment.

Failed & De-adopted Therapies (Honest Talk)

You’ll see online claims about “breakthroughs.” Being able to tell proven from unproven — and knowing what has actually failed — protects you. Several once-promising drugs were tested rigorously and did not work for ADPKD:

Bardoxolone methyl — a Phase 3 trial (FALCON, NCT03918447) was stopped in 2023; it did not deliver the expected benefit, and development for ADPKD was discontinued. Not recommended.
Venglustat — a Phase 2/3 trial (STAGED-PKD, NCT03523728) was stopped early for futility in 2021; it showed no benefit and a faster decline in kidney function. Not recommended.
Lixivaptan — another vasopressin blocker hoped to be a tolvaptan alternative with less liver risk; its ADPKD program (ACTION and ALERT trials) was discontinued in 2022 after liver-enzyme signals appeared in people who had previously reacted to tolvaptan. Not currently available.
mTOR inhibitors (sirolimus, everolimus) — trials did not show meaningful kidney-function benefit and caused notable side effects; not used to treat ADPKD.
Somatostatin analogs for the kidney — drugs like octreotide/lanreotide can modestly shrink kidney and liver volume, but trials (e.g., DIPAK-1, ALADIN) did not establish a clear kidney-function benefit, so they are not standard for protecting kidney function (they remain an option for severe liver cysts in selected people).
Tyrosine-kinase inhibitors (e.g., bosutinib, tesevatinib) — tested and did not pan out for ADPKD.

The lesson isn’t pessimism — it’s discernment. Rely on proven therapy (blood-pressure control; tolvaptan for high-risk ADPKD), and treat new claims with healthy skepticism unless they come from well-run, registered trials. Ask your team before trying anything you read about online.

Specialty Center Directory

PKD care benefits from clinicians experienced in inherited/cystic kidney disease — for risk stratification (MRI kidney volume), tolvaptan therapy and monitoring, complication management, genetic counseling, and transplant (including donor genetic screening). Phone numbers change; please verify before calling.

University of Utah Health — Division of Nephrology & Hypertension (Salt Lake City). Inherited/cystic kidney disease care: diagnosis, genetic counseling referral, MRI total-kidney-volume risk stratification, tolvaptan therapy with required liver monitoring, complication management, and kidney transplantation. Main scheduling/health line: 801-581-2121.
University of Utah Transplant Program & Dialysis Services. Kidney transplant evaluation, living-donor program (with genetic screening of potential related donors), and dialysis-access planning. 801-585-2901 (transplant).
University of Utah Genetic Counseling Services. Inheritance education, genetic testing, and reproductive options including preimplantation genetic testing. Ask your nephrologist for a referral, or call 801-581-2121.
Intermountain Health — Nephrology & Kidney Transplant Services (Wasatch Front & statewide). PKD care, blood-pressure management, dialysis, and transplant evaluation. Intermountain Medical Center (Murray): 801-507-7000.
George E. Wahlen Department of Veterans Affairs Medical Center (Salt Lake City) — Nephrology. PKD care for veterans. 801-582-1565 (main).

The PKD Foundation designates Centers of Excellence; examples of major programs with deep PKD expertise include:

Mayo Clinic (Rochester, MN) — the home of the Mayo Imaging Classification and a leading PKD translational program. 507-284-2511.
University of Colorado (Aurora, CO) — long-standing PKD research and care. 720-848-0000.
Cleveland Clinic (Cleveland, OH) — comprehensive PKD and transplant. 800-223-2273.
University of Kansas Medical Center (Kansas City, KS) — PKD research center (CRISP legacy). 913-588-5000.
Tufts Medical Center (Boston, MA) and University of Maryland (Baltimore, MD) — PKD clinical-trial centers (e.g., TAME-PKD). Tufts 617-636-5000; UMD 410-328-8000.
UCSF (San Francisco, CA) — PKD Center of Excellence. 415-476-1000.

Find the current list and a center near you via the PKD Foundation (pkdcure.org).

VA Salt Lake City Health Care System (George E. Wahlen VAMC) — nephrology services for veterans, including PKD. 801-582-1565.
Most VA medical centers have nephrology; complex PKD care (tolvaptan, transplant) may be referred to a VA transplant center or community care. Ask about service connection if kidney disease is related to military service, which can affect benefits and coverage.
The VA covers tolvaptan through its formulary with criteria; your VA nephrologist and pharmacy can advise on eligibility and the monitoring program.

Major academic nephrology programs (e.g., Toronto General/UHN, St. Michael’s (Toronto), University of British Columbia (Vancouver), University of Alberta (Edmonton), McGill (Montreal)) offer PKD and transplant care.
Drug coverage note: tolvaptan (Jinarc) is approved by Health Canada and funded by provincial programs under specific eligibility criteria (rapid-progression criteria, kidney function thresholds) with required liver monitoring; coverage details vary by province. The Canadian Society of Nephrology has published ADPKD guidance.
The PKD Foundation of Canada offers education and support.

Europe: ERKNet (European Rare Kidney Disease Reference Network) links expert centers across Europe; major programs include those in the Netherlands (Groningen — DIPAK studies), France (Brest/Paris — filière ORKID), Germany (Cologne), and the UK (Sheffield, London).
UK: specialist inherited-kidney-disease clinics; tolvaptan is available via the NHS under NICE criteria.
Japan: tolvaptan was first approved here for ADPKD; the Japanese Society of Nephrology runs ADPKD guidelines and expert centers.
Australia/New Zealand: the PREVENT-ADPKD program (Westmead, Sydney) and KHA-CARI guidance; tolvaptan available under PBS criteria.

PKD Foundation (pkdcure.org) — education, peer mentors, a chapter network, an ADPKD registry, a clinical-studies finder, financial-assistance information, and a help line.
National Kidney Foundation (kidney.org) — broad kidney education, dialysis/transplant resources, and support.
ClinicalTrials.gov — the US trial registry.

International Access & Regulatory Landscape

The way PKD is managed is remarkably consistent worldwide — blood-pressure control, risk stratification, and tolvaptan for rapid progressors. What differs is access: who qualifies for tolvaptan, how it’s paid for, and how readily genetic testing and MRI kidney-volume measurement are available.

One global guideline now anchors care. In 2025, KDIGO published the first global ADPKD guideline, harmonizing diagnosis, risk assessment, and tolvaptan use across countries — a milestone that makes care more consistent everywhere.

Region	Tolvaptan brand & status	Notes on access
United States	Jynarque — FDA-approved (2018) for rapidly progressing ADPKD	Dispensed through a restricted program (REMS) with mandatory liver monitoring; specialty pharmacy and prior authorization usually required.
Europe (EU)	Jinarc — EMA-approved	Eligibility per rapid-progression criteria; reimbursement and exact criteria vary by country; liver monitoring required.
United Kingdom	Jinarc — available via NHS	Use guided by NICE criteria (CKD stage and evidence of rapid progression).
Japan	Jinarc (Samsca) — first country to approve tolvaptan for ADPKD (2014)	PMDA-approved; established monitoring; specific eligibility criteria.
Canada	Jinarc — Health Canada-approved	Provincial funding under criteria; liver monitoring required.
Australia/NZ	Jinarc — approved	Available under PBS (Australia) criteria; liver monitoring required.
China	Tolvaptan — approved for ADPKD (NMPA)	Access and reimbursement expanding; criteria apply.

Eligibility criteria, reimbursement, and monitoring logistics change over time and differ by health system. Confirm current local details with your nephrologist or national kidney society. Genetic-testing and MRI-volume access also vary by region, which can affect how readily your risk is formally stratified.

Glossary (Plain-Language)

ADPKD — autosomal dominant polycystic kidney disease; the common adult, inherited form.
ARPKD — autosomal recessive PKD; the rare, severe childhood form (gene PKHD1), also affecting the liver.
Aneurysm (intracranial) — a weak, balloon-like spot on a brain artery; rarely ruptures, but serious if it does.
Aquaresis — the heavy free-water urination caused by tolvaptan.
Cyst — a fluid-filled sac; in PKD, cysts grow in the kidneys (and often liver).
eGFR — estimated glomerular filtration rate; a blood-test measure of how well the kidneys filter. Higher is better.
htTKV / total kidney volume — the size of the kidneys measured on MRI, adjusted for height; used to predict progression.
Hypertension — high blood pressure.
Mayo Imaging Classification — a system (classes 1A–1E) that uses kidney volume and age to predict how fast ADPKD will progress.
Nephrectomy — surgical removal of a kidney; in PKD, sometimes done for very large/troublesome native kidneys.
Nephrologist — a kidney-specialist doctor.
PROPKD score — a 0–9 score using sex, early hypertension, early urological events, and gene type to estimate progression risk.
RAAS — the renin–angiotensin–aldosterone system; a hormone system overactive in PKD that ACE inhibitors/ARBs block.
REMS — the US safety program that organizes tolvaptan’s required liver monitoring.
Tolvaptan — the first disease-slowing drug for ADPKD (Jynarque/Jinarc), a vasopressin V2-receptor blocker.
Vasopressin — a hormone that drives cyst growth in PKD; water intake lowers it, and tolvaptan blocks it.

Key References & Sources

This guide draws on major guidelines, landmark trials, and authoritative organizations. Identifiers are provided so you or your clinician can look them up.

KDIGO 2025 Clinical Practice Guideline for ADPKD — the first global ADPKD guideline. Kidney International 2025;107(2S):S1–S239 (PubMed ID 39848759). Executive summary also in Kidney International 2025;107:234–254.
TEMPO 3:4 (tolvaptan, earlier stage) — Torres VE et al., New England Journal of Medicine 2012;367:2407–2418 (PubMed ID 23121377). Trial: NCT00428948.
REPRISE (tolvaptan, later stage) — Torres VE et al., New England Journal of Medicine 2017;377:1930–1942. Trial: NCT02160145.
HALT-PKD Study A (early disease, blood pressure) — Schrier RW et al., NEJM 2014;371:2255–2266. Trial: NCT00283686.
HALT-PKD Study B (advanced disease, RAAS) — Torres VE et al., NEJM 2014;371:2267–2276. Trial: NCT01885559.
Mayo Imaging Classification — Irazabal MV et al., Journal of the American Society of Nephrology 2015;26:160–172.
PROPKD score — Cornec-Le Gall E et al., JASN 2016;27:942–951.
Lanreotide for kidney function (DIPAK-1) — Meijer E et al., JAMA 2018;320:2010–2019.
Failed: bardoxolone (FALCON) — NCT03918447 (terminated 2023).
Failed: venglustat (STAGED-PKD) — Gansevoort RT et al., American Journal of Kidney Diseases 2023; trial NCT03523728 (stopped for futility).
Metformin (TAME-PKD) — Perrone RD et al., Kidney International 2021;100:684–696. Trial: NCT02656017.
Organizations: PKD Foundation (pkdcure.org); National Kidney Foundation (kidney.org); FDA (Jynarque label & REMS); EMA (Jinarc); KDIGO (kdigo.org).

Final disclaimer. This guide is for education only and is not medical advice. PKD management is individualized and evidence is evolving. Always make decisions with your own nephrology team. Verify drug eligibility, monitoring requirements, trial status, and center contact details directly, as these change over time.

A Research Guide for
PKD

⚡ Quick Start — If You Read Nothing Else

Understanding PKD: The Big Picture

Genetics & Family Testing: What Runs in the Family

The dominant adult form (ADPKD)

The recessive childhood form (ARPKD)

How PKD Is Diagnosed — and How Fast It May Progress

Making the diagnosis

Predicting the future: the single most empowering part of modern PKD care

Tracking kidney function over time

Blood Pressure & Protecting Your Kidneys: The Foundation

What the research showed (the HALT-PKD trials)

Tolvaptan & Managing Cyst Complications

Tolvaptan: the first medicine that slows PKD

The evidence (TEMPO 3:4 and REPRISE)

Who is a candidate?

Managing cyst complications

Beyond the Kidneys: Liver Cysts & Brain-Aneurysm Screening

Polycystic liver disease

Brain (intracranial) aneurysm screening

Planning for Kidney Failure (If It Comes)

Understanding your options

Transplant & Living Well

Support & Resources

Caregiver Toolkit (Notes & Practical Tips)

>Clinical Trials — Finding and Joining

Failed & De-adopted Therapies (Honest Talk)

Specialty Center Directory

International Access & Regulatory Landscape

Glossary (Plain-Language)

Key References & Sources

⚠️ Safety Warnings & Critical Drug Risks

Tolvaptan (Jynarque) — FDA Boxed Warning: Serious & Fatal Hepatotoxicity

Kidney Protection — Avoid Nephrotoxins as eGFR Declines

A Research Guide forPKD

⚡ Quick Start — If You Read Nothing Else

Understanding PKD: The Big Picture

Genetics & Family Testing: What Runs in the Family

The dominant adult form (ADPKD)

The recessive childhood form (ARPKD)

How PKD Is Diagnosed — and How Fast It May Progress

Making the diagnosis

Predicting the future: the single most empowering part of modern PKD care

Tracking kidney function over time

Blood Pressure & Protecting Your Kidneys: The Foundation

What the research showed (the HALT-PKD trials)

Tolvaptan & Managing Cyst Complications

Tolvaptan: the first medicine that slows PKD

The evidence (TEMPO 3:4 and REPRISE)

Who is a candidate?

Managing cyst complications

Beyond the Kidneys: Liver Cysts & Brain-Aneurysm Screening

Polycystic liver disease

Brain (intracranial) aneurysm screening

Planning for Kidney Failure (If It Comes)

Understanding your options

Transplant & Living Well

Support & Resources

Caregiver Toolkit (Notes & Practical Tips)

>Clinical Trials — Finding and Joining

Failed & De-adopted Therapies (Honest Talk)

Specialty Center Directory

International Access & Regulatory Landscape

Glossary (Plain-Language)

Key References & Sources

⚠️ Safety Warnings & Critical Drug Risks

Tolvaptan (Jynarque) — FDA Boxed Warning: Serious & Fatal Hepatotoxicity

Kidney Protection — Avoid Nephrotoxins as eGFR Declines

A Research Guide for
PKD